Fairmount Funds Management LLC 13D and 13G filings for Spyre Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-04-25 4:40 pm Purchase |
2024-04-23 | 13D | Spyre Therapeutics, Inc. SYRE |
Fairmount Funds Management LLC | 4,508,579 11.170% |
3,672,120 (+439.01%) |
Filing |
| 2023-12-29 5:00 pm Sale |
2023-12-29 | 13D | Spyre Therapeutics, Inc. SYRE |
Fairmount Funds Management LLC | 836,459 2.320% |
-2,977,442 (-78.07%) |
Filing |
| 2023-12-11 5:21 pm Unchanged |
2023-12-07 | 13D | Spyre Therapeutics, Inc. SYRE |
Fairmount Funds Management LLC | 3,813,901 10.590% |
0 (Unchanged) |
Filing |
| 2023-11-29 5:08 pm Purchase |
2023-11-24 | 13D | Spyre Therapeutics, Inc. SYRE |
Fairmount Funds Management LLC | 3,813,901 12.700% |
3,813,901 (New Position) |
Filing |